Regulatory issues in developing new HIV protease inhibitors: risks and benefits.

Saved in:
Bibliographic Details
Title: Regulatory issues in developing new HIV protease inhibitors: risks and benefits.
Authors: Struble KA; Office of New Drugs, Office of Antimicrobial Products, Division of Antiviral Products, US Food and Drug Administration, USA. Kimberly.struble@fda.hhs.gov, Chan-Tack KM, Soon GG
Source: Current opinion in HIV and AIDS [Curr Opin HIV AIDS] 2008 Nov; Vol. 3 (6), pp. 676-80.
Publication Type: Journal Article
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101264945 Publication Model: Print Cited Medium: Internet ISSN: 1746-6318 (Electronic) Linking ISSN: 1746630X NLM ISO Abbreviation: Curr Opin HIV AIDS Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1746-6318
DOI:10.1097/COH.0b013e3283136cb1